13F reference period
Q2 2026
Security Snapshot
Terns Pharmaceuticals, Inc. - Common Stock (TERN) Institutional Ownership
CUSIP: 880881107
13F Institutional Holders and Ownership History from Q1 2021 to Q3 2026
Institutions Reporting
2
Shares (Excl. Options)
12.51K
Full value: 12,507 · shares · 30 Jun 2026Price
$52.84
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- TERN
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 12,507
- Total 13F value
- $659,697
- Share change
- -123,063,719
- Value change
- -$6,474,017,365
- Number of holders
- 2
- Shares outstanding
- 115,479,185
- SEC-reported price per share
- $52.95
- Insider filing price
- $52.95
Latest holder snapshot
4 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- TERN - Terns Pharmaceuticals, Inc. - Common Stock is tracked under CUSIP 880881107.
- 2 institutions reported positions in Q2 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 316 to 2 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$6.56B
Full value: $6,563,964,853 · USD · 31 Mar 2026.$659.7K
Full value: $659,697 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 2 institutions filings for Q2 2026.
Security key
880881107
13F reference period
Q2 2026
13F holders
2
13D/G owners
9
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 880881107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
TERN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 6.8% | $16,770,967 | 5,743,482 | BlackRock, Inc. | 31 Dec 2024 | |||
| Schonfeld Strategic Advisors LLC | 4.9% | -20% | $12,571,196 | -$2,713,568 | 4,305,204 | -18% | Schonfeld Strategic Advisors LLC | 31 Mar 2025 |
| ORBIMED ADVISORS LLC | 4.8% | $31,842,911 | 4,240,068 | ORBIMED ADVISORS LLC | 03 Nov 2025 | |||
| CITADEL ADVISORS LLC | 4.1% | $10,118,696 | 3,465,307 | Kenneth Griffin | 31 Dec 2024 | |||
| Deep Track Capital, LP | 3% | -62% | $111,762,000 | -$154,160,600 | 3,150,000 | -58% | Deep Track Capital, LP | 31 Dec 2025 |
| Vivo Opportunity Fund Holdings, L.P. | 2.5% | $95,817,820 | 2,700,615 | Vivo Opportunity Fund Holdings, L.P. | 31 Jan 2025 | |||
| Adage Capital Management, L.P. | 1.8% | -65% | $111,829,119 | -$180,267,381 | 2,124,817 | -62% | Adage Capital Management, L.P. | 31 Mar 2026 |
| Commodore Capital LP | 1.4% | -73% | $52,333,000 | -$149,903,000 | 1,475,000 | -74% | Commodore Capital LP | 31 Dec 2025 |
| Soleus Capital Master Fund, L.P. | 0.2% | -94% | $7,546,951 | -$281,348,949 | 212,710 | -97% | Soleus Capital Master Fund, L.P. | 31 Dec 2025 |
As of 30 Jun 2026,
2
institutional investors reported holding
shares of
Terns Pharmaceuticals, Inc. - Common Stock (TERN).
This represents
0.01%
of the company’s total
outstanding shares.
12.51K
Full value: 12,507 · shares · 30 Jun 2026115.48M
Full value: 115,479,185 · shares · Stored outstanding share countQuarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
23
Headline period
Q2 2026
Rows shown
1-23 of 23
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 0 | $0 | -$75,401 | $52.95 | 0 |
| 2026 Q2 | 12,507 | $659,697 | -$6,474,017,365 | $52.84 | 2 |
| 2026 Q1 | 124,769,660 | $6,563,964,853 | +$285,158,551 | $52.72 | 316 |
| 2025 Q4 | 122,594,176 | $4,952,941,227 | +$1,340,517,762 | $40.40 | 247 |
| 2025 Q3 | 88,633,130 | $665,700,838 | +$50,617,366 | $7.51 | 140 |
| 2025 Q2 | 83,108,168 | $309,995,477 | +$2,354,788 | $3.73 | 126 |
| 2025 Q1 | 83,089,113 | $229,386,277 | -$20,904,178 | $2.76 | 134 |
| 2024 Q4 | 86,147,142 | $477,240,000 | +$3,828,882 | $5.54 | 156 |
| 2024 Q3 | 79,491,087 | $663,002,763 | +$119,235,330 | $8.34 | 153 |
| 2024 Q2 | 65,586,958 | $446,681,549 | +$17,184,836 | $6.81 | 124 |
| 2024 Q1 | 63,239,404 | $414,841,261 | -$1,823,851 | $6.56 | 112 |
| 2023 Q4 | 63,584,855 | $412,672,679 | +$14,024,936 | $6.49 | 102 |
| 2023 Q3 | 61,708,912 | $310,396,950 | +$8,574,392 | $5.03 | 92 |
| 2023 Q2 | 57,715,917 | $505,015,397 | +$31,653,493 | $8.75 | 102 |
| 2023 Q1 | 53,226,532 | $630,202,113 | +$46,248,002 | $11.84 | 79 |
| 2022 Q4 | 49,723,793 | $506,193,882 | +$199,453,477 | $10.18 | 65 |
| 2022 Q3 | 30,203,299 | $177,898,000 | +$107,051,162 | $5.89 | 43 |
| 2022 Q2 | 14,707,603 | $36,472,000 | -$6,462,439 | $2.48 | 37 |
| 2022 Q1 | 16,836,162 | $50,004,000 | -$1,388,822 | $2.97 | 43 |
| 2021 Q4 | 16,503,387 | $116,663,000 | -$4,531,477 | $7.07 | 37 |
| 2021 Q3 | 16,724,968 | $174,276,000 | +$979,766 | $10.42 | 33 |
| 2021 Q2 | 16,621,217 | $203,777,000 | -$24,794,385 | $12.26 | 36 |
| 2021 Q1 | 17,905,204 | $393,648,000 | +$393,098,000 | $22.00 | 41 |